On May 28, 2018 Biotecnol and University of Naples reported that published a study on Journal of Immunology, Volume 40 – Issue 4 – p 117, showing the flexibility and versatility of its Tribody and Trisoma platforms (Press release, Biotecnol, MAY 28, 2018, View Source [SID1234570280]). The team assembled a multiparatope Tribody Tb-TPE which was able to bind to a wider population of tumor cells as it also recognized epitopes present in trastuzumab-resistant tumour cells expressing a receptor that either lacks some extracellular regions, such as the oncogenic D16HER2 variant, or masks some domains in the interaction with other receptors, such as MUC4 in JIMT-1 cells, CD44 or other membrane surface proteins in other cell lines, thus providing a useful tool to overcome resistance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new construct combines in 1 single molecule 3 different targeting approaches and antitumor actions of 3 different antibodies, such as trastuzumab, pertuzumab, and a proprietary anti-HER2 binder which recognises a different epitope, and it allows to reduce the costs of antibody production as only 1 construct provides the effects of 3 different antibodies.

The study concluded that a triparatope Tribody to ErbB2/ HER2 had the potential to become a best-in-class therapeutic to address monotherapy drug resistance and tumour heterogeneity and therefore bring clinical benefits for longer periods of time and to a larger patient population. Furthermore such an approach could be used in immune-modulation with key immune-checkpoints.